The Efficacy and Safety of Topical Cyclosporine A and its Generic Equivalency Depores Eye Drops in The Treatment of Dry Eye Disease
Review
##plugins.pubIds.doi.readerDisplayName##:
https://doi.org/10.61699/cjmps-v2-i1-2-p50-68关键词:
Cyclosporin A, Restasis, Ikervis, Depores, dry eye disease摘要
Dry eye disease (DED) is a complex condition that can result in significant vision complications. Analyzing systematic reviews of DED treatment contributes to selecting the most effective and safe drug. This review examines the efficacy of cyclosporine A and the generic Depores ophthalmic emulsion cyclosporine 0.05% (cyclosporine 0.05%, Deva Pharmaceuticals, Turkey) in the treatment of DED. A search for scientific information in PubMed, PubMed Central, The Cochrane Library, Google Scholar databases, and the Internet was carried out using keywords: dry eye disease, Cyclosporine A, Ikervis, Restasis, generic cyclosporine 0.05% ophthalmic emulsion, Depores. The literature cited in scientific articles was also reviewed. The analysis of scientific articles allowed us to conclude about the efficacy of the Restasis–Depores generic (cyclosporine 0.05%, Deva Pharmaceuticals, Turkey) for the treatment of patients with DED who have not yet had access to this treatment. Depores is now available in Georgia, bringing a novel treatment option to patients with severe DED. The study revealed a small number of clinical studies evaluating the efficacy and safety of generic cyclosporine 0.05% ophthalmic emulsion. Given the scarcity of research articles on this generic, it is necessary to study the results of its use in the treatment of DED in Georgia, which will help improve the quality of life with a diagnosis of dry eye.
参考
Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluat ion of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112: 1790-4.
Bayrakceken, K, Ugurlu, A. Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction. Revista Brasileira de Oftalmologia [online]. 2022, v. 81. https:// doi.org/10.37039/1982.8551. 20220044 3.
Bayraktutar BN, Uçakhan ÖÖ. Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates. Case Rep Ophthalmol. 2016;7(1):135140. Published 2016 Mar 8. doi:10.1159/000444784.
Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246-258.
Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520-530. doi:10.5301/EJO.5000952.
Baudouin C, de la Maza MS, Amrane M, et al. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. Eur J Ophthalmol. 2017;27(6):678-685. doi:10.5301/ ejo.5001002.
Baudouin C, Rolando M, Benitez Del Castillo JM, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res. 2019;71:6887. doi:10.1016/j.preteyeres.2018.11.007.
Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9):1027-1039. doi:10.1080/14656566.2018. https://doi.org/10.1080/14656566.2018.1479742.
Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6(4):468-475. doi:10.1007/BF01973261.
Borel JF. Cyclosporin-A--present experimental status. Transplant Proc. 1981;13(1 Pt 1):344-348.
Branded vs. Generics: You make the call. Ophthalmology Times. December 6, 2018. Available at: https://www.ophthalmologytimes.com/article/branded-vs-generics-youmake-call.
Brignole-Baudouin F, Riancho L, Ismail D, et al. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease. Invest Ophthalmol Vis Sci. 2017;58(4):2438-2448. doi:10.1167/iovs.15-16555.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438510. doi:10.1016/j.jtos.2017.05.011.
Brzheskiy VV. Sovremennye vozmozhnosti patogeneticheski orientirovannoi terapii sindroma «sukhogo glaza» [Modern possibilities of pathogenetically oriented therapy for dry eye syndrome]. Vestn Oftalmol. 2023;139(2):95-103. doi:10.17116/oftalma202313902195 [in Russian]
Cosar CB, Kilavuzoglu AE, Altıparmak UE, Cenk Çelebi AR. Generic Cyclosporine in the Treatment of Dry Eye Disease. Acıbadem Univ. Sağlık Bilim. Derg. 2022; 13 (2): 241-246 .
Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802-812. doi:10.1016/j.jtos.2017.08.003.
Deshmukh R, Ting DSJ, Elsahn A, Mohammed I, Said DG, Dua HS. Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 2022;106(8):10871092. doi:10.1136/bjophthalmol-2020-317907.
Dhillion SS, Svarstad H, Amundsen C, Bugge HC. Bioprospecting: effects on environment and development. Ambio. 2002;31(6):491-493. doi:10.1579/0044-7447-31.6.491.
Duran T, Karakuş O, Değim İT, Eser B, Sezigen S, Güney Z, Uluoğlu C. Evaluating of Two Type of Cyclosporine-A Containing Nanosuspension for Ophthalmic Administration. JBACHS. 2021;5:107–116. https://doi.org/10.30621/jbachs.926640.
European Medicines Agency, Generic and Hybrid Medicines. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/generic-hybridmedicines.
FDA. FDA Approves First Generic of Restasis. 2022 [updated 2022 Feb 2; cited 2022 Sep 22]. Available from: https://www.fda.gov/newsevents/press-announcements/fdaapproves-first-generic-restasis.
FDA. Highlights of prescribing information: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%. 2013. [cited 2022 Sep 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
Food and Drug Administration. Restasis (cyclosporine ) ophthalmic label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050790s027lbl.pdf
Gouider D, Khallouli A, Maalej A, et al. Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study. Cornea. 2021;40(6):726-732. doi:10.1097/ICO.0000000000002589;
Hirschberg J. The History of Ophthalmology, Vol. 1: Antiquity. Translated by FC Blodi. Bonn, West Germany: Verlag JP Wayenborgh, 1982
Holland EJ, Darvish M, Nichols KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. Ocul Surf 2019; 17: 412-23.
Holly FJ. Formation and rupture of the tear film. Exp Eye Res. 1973;15(5):515-525. doi:10.1016/0014-4835(73)90064-x.
Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30:958–961.
Jerkins GW, Pattar GR, Kannarr SR. A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca. Clin Ophthalmol. 2020;14:481489. Published 2020 Feb 20. doi:10.2147/OPTH.S228070.
Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015;60:435–443.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15: 575-628.
Ikervis summary of product characteristics. Revised 01/2018. Santen SAS. Available at: https://www.medicines.org.uk/emc/product/6937/ smpc/history. Accessed Feb. 14, 2018.
Karpecki PM. The evaluation of dry eye. Review of Optometry. 2015. https://www.reviewofoptometry.com/article/the-evolution-of-dryeye.
Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. BMC Ophthalmol. 2023;23(1):443. Published 2023 Nov 2. doi:10.1186/s12886023-03174-y
Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine.Clin Ophthalmol. 2008;2(4):829-836. doi:10.2147/opth.s1409
Labetoulle M, Leonardi A, Amrane M, et al. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. Clin Ther. 2018;40(11):1894-1906. doi:10.1016/j.clinthera.2018.09.012
Labetoulle M, Leonardi A, Pisella PJ, Baudouin C. Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers. Ocul Immunol Inflamm. 2023;31(8):17071715. doi:10.1080/09273948.2022.2088566
Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012: 604204
Leonardi A, Van Setten G, Amrane M, et al. Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial. European Journal of Ophthalmology. 2016;26(4):287-296. doi:10.5301/ejo.5000779
Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125-131. doi:10.1136/bjophthalmol-2017-311801
Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivit is. Cornea. 2010;29:638–640.
Levy O, Labbé A, Borderie V, Laroche L, Bouheraoua N. La cyclosporine topique en ophtalmologie : pharmacologie et indications thérapeutiques. J Fr Ophtalmol. 2016;39(3):292-307. doi:10.1016/j. jfo.2015.11.008.
Ling J, Chan BC, Tsang MS, et al. Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine. Front Med (Lausanne). 2022;8:815075. Published 2022 Jan 17. doi:10.3389/ fmed.2021.815075.
Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348-361. doi:10.1097/ ICU.0000000000000768.
Napoli PE, Braghiroli M, Iovino C, Demarinis G, Fossarello M. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops. Drug Des Devel Ther. 2019;13:20012008. Published 2019 Jun 19. doi:10.2147/DDDT.S207453.
Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269-275. doi:10.1016/j.jtos.2017.05.005. de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-1122. Published 2019 Jul 1. doi:10.2147/OPTH.S184412.
Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, Erbagci I, Gurler B. Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol. 2012;18:12–42.
Patel D, Wairkar S. Recent advances in cyclosporine drug delivery. Challenges and opportunities. Drug Delivery and Translational Research 2019; 9: 1067-81.
Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342. doi:10.1016/j.ajo.2003.10.036.
Pflugfelder SC, Stern ME. The cornea in keratoconjunctivitis sicca. Exp Eye Res. 2020;201:108295. doi:10.1016/j.exer.2020.108295. van Setten G, Labetoulle M, Baudouin C, Rolando M. Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol. 2016;94(5):499-506. doi:10.1111/aos.12985.
Shen Lee B, Toyos M, Karpecki P, Schiffbauer J, Sheppard J. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials. Ophthalmol Ther. 2022;11(4):1333-1369. doi:10.1007/s40123-022-00516-9.
Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclo sporine 0.05%. Eye & Contact Lens. 2014; 40: 289-96.
Schulltz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 2014; 6: 37-4.
Singla S, Sarkar L, Joshi M. Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population. A prospective study. Taiwan J Ophthalmol 2019; 9: 173-8.
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–365.
Stevenson D, Tauber J, Reis BL. Eff icacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporine a phase 2 study group. Ophthalmology 2000; 107: 967-74.
Tavares Fde P, Fernandes RS, Bernardes TF, Bonfioli AA, Soares EJ. Dry eye disease. Semin Ophthalmol. 2010;25(3):84-93. doi:10.3109/0882 0538.2010.488568.
Valencia-Nieto L, Pinto-Fraga J, Blanco-Vázquez M, et al. Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment. Ophthalmol Ther. 2024;13(5):1197-1210. doi:10.1007/s40123-024-00906-1.
Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15-34. doi:10.1016/s1350-9462(01)00017-9.
Wan KH, Chen LJ, Young AL. Efficacy and safety of topical %0.05 cyclosporine eye drops in the treatment of dry eye syndrome: A systematic review and meta-analysis. Ocul Surf 2015. 13:213-25.
Zghal I, Fekih O, Zgolli HM, Chargui S, Malek I, Nacef L. Cyclosporin A eye drop and subepithelial adenoviral keratoconjunctivitis infiltrates. Tunis Med. 2019;97(5):639-643.
https://ec.europa.eu/health/documents/community-register/2015/20150319131066/anx_131066_en.pdf https://www.santen.com/asia/therapeutic-areas/dryeye/ikervis
https://www.rxreasoner.com/drugs/depores https://prospektus.co/ilac/depores-x-0-1-goz-damlasi-emulsiyon-30-flakon/
